Management of Persistent Leukocytosis After Pneumonia Treatment

Initial Assessment

For patients who fail to improve as expected after pneumonia treatment, conduct a thorough review of the clinical history, examination, prescription chart, and results of all available investigations 1
Assess for specific signs and symptoms including fever, respiratory rate, pulse, blood pressure, mental status, oxygen saturation, and inspired oxygen concentration 2
Monitor these vital signs at least twice daily, and more frequently in those with severe pneumonia or requiring regular oxygen therapy 2

Obtain a repeat chest radiograph in patients who are not progressing satisfactorily 1, 3
Remeasure C-reactive protein (CRP) level and white blood cell count to evaluate ongoing inflammation 1, 3
Consider collecting additional specimens for microbiological testing based on new information after clinical review 1
An elevated white blood cell count (>14,000 cells/mm³) or left shift (percentage of band neutrophils >16% or total band neutrophil count >1,500 cells/mm³) warrants careful assessment for bacterial infection 4

When a change in empirical antibiotic treatment is necessary, consider the following options: add or substitute a macrolide (erythromycin or clarithromycin) for non-severe pneumonia initially treated with amoxicillin monotherapy 1
For non-severe pneumonia on combination therapy, consider changing to a fluoroquinolone with effective pneumococcal coverage 1
For severe pneumonia not responding to combination treatment, consider adding rifampicin 1
For patients with severe microbiologically undefined pneumonia, 10 days of treatment is proposed 1
Extend treatment to 14-21 days where Legionella, staphylococcal, or Gram-negative enteric bacilli pneumonia are suspected or confirmed 1
For patients with non-severe and uncomplicated pneumonia, 7 days of appropriate antibiotics is typically sufficient 6

Ensure appropriate oxygen therapy with monitoring of oxygen saturations to maintain SaO₂ >92% 2
Assess for volume depletion and provide intravenous fluids if needed 2
Provide nutritional support in cases of prolonged illness 2

Consider bronchoscopy in patients with persisting signs, symptoms, and radiological abnormalities about 6 weeks after completing treatment 2, 3

Arrange clinical review for all patients at around 6 weeks, either with their general practitioner or in a hospital clinic 7
A chest radiograph should be arranged at follow-up for patients who have persistent symptoms or physical signs, or who are at higher risk of underlying malignancy (especially smokers and those over 50 years) 7

Assuming radiological improvement will match clinical improvement; radiological changes often lag behind clinical recovery 3
Failing to consider resistant organisms or atypical pathogens not covered by initial therapy 5